NF-κB as a potential molecular target for cancer therapy
Article first published online: 19 DEC 2008
Copyright © 2007 International Union of Biochemistry and Molecular Biology, Inc.
Volume 29, Issue 1, pages 19–35, 2007
How to Cite
Lee, C. H., Jeon, Y.-T., Kim, S.-H. and Song, Y.-S. (2007), NF-κB as a potential molecular target for cancer therapy. BioFactors, 29: 19–35. doi: 10.1002/biof.5520290103
- Issue published online: 19 DEC 2008
- Article first published online: 19 DEC 2008
- Manuscript Accepted: 20 JAN 2007
- Manuscript Received: 19 NOV 2006
- Basic Research Program 2005, Ministry of Science & Technology Control, Republic of Korea. Grant Number: (R01–2005–000–10230–0
- NF-κB inhibitor;
- cancer therapy
Nuclear factor κB (NF-κB), a transcription factor, plays an important role in carcinogenesis as well as in the regulation of immune and inflammatory responses. NF-κB induces the expression of diverse target genes that promote cell proliferation, regulate apoptosis, facilitate angiogenesis and stimulate invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NF-κB activation which mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NF-κB activation and its signaling pathway offers a potential cancer therapy strategy. In addition, recent studies have shown that NF-κB can also play a tumor suppressor role in certain settings. In this review, we focus on the role of NF-κB in carcinogenesis and the therapeutic potential of targeting NF-κB in cancer therapy.